Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 1—January 2003
Perspective

Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

W. Michael Scheld*Comments to Author 
Author affiliation: *University of Virginia, School of Medicine, Charlottesville, Virginia, USA

Main Article

Table 2

Comparison of pharmacokinetic and pharmacodynamic parameters for four fluoroquinolones and selected bacterial speciesa

Streptococcus pneumoniae Pseudomonas aeruginosa
Fluoroquinolone
 Dose
(mg)
 Cmaxa,b
(mg/L)
 AUC24b
(mg x h/L)
 MICc
 Cmax:MIC
 AUIC
 MICc
 Cmax:MIC
 AUIC
Ciprofloxacin
 500
 3.0
 28
 2
 1.5
 14
 4
 0.75
 7
750
 3.6
 32
 2
 1.8
 16
 4
 0.9
 8
Levofloxacin
 500
 5.7
 48
 1
 5.7
 48
 16
 0.36
 3
Moxifloxacin
 400
 4.5
 48
 0.25
 18
 192
 8
 0.56
 6
Gatifloxacin 400 4.2 34 0.5 8.4 68 8 0.52 4.25

aCmax, peak serum concentration of the drug; AUC, area under the curve; MIC, minimal inhibitory concentration; AUIC, ratio of the AUC to MIC.
bReferences 41–44.
cReference 16.

Main Article

References
  1. Holmberg  SD, Solomon  SL, Blake  PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987;9:1065–78.PubMedGoogle Scholar
  2. Linden  PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med. 1998;104:24S–33. DOIPubMedGoogle Scholar
  3. U.S. Congress, Office of Technology Assessment. Impacts of antibiotic-resistant bacteria. OTA-H-629. Washington: U.S. Government Printing Office; 1995.
  4. Rice  LB, Willey  SH, Papanicolaou  GA, Medeiros  AA, Eliopoulos  GM, Moellering  RC Jr, Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990;34:2193–9.PubMedGoogle Scholar
  5. Chow  JW, Fine  MJ, Shlaes  DM, Quinn  JP, Hooper  DC, Johnson  MP, Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585–90.PubMedGoogle Scholar
  6. Meyer  KS, Urban  C, Eagan  JA, Berger  BJ, Rahal  JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119:353–8.PubMedGoogle Scholar
  7. Rice  LB, Eckstein  EC, DeVente  J, Shlaes  DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 1996;23:118–24.PubMedGoogle Scholar
  8. Kollef  MH, Vlasnik  J, Sharpless  L, Pasque  C, Murphy  D, Fraser  V, Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997;156:1040–8.PubMedGoogle Scholar
  9. Hooper  DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis. 2000;30:243–54. DOIPubMedGoogle Scholar
  10. Munshi  MH, Sack  DA, Haider  K, Ahmed  ZU, Rahaman  MM, Morshed  MG. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type I. Lancet. 1987;2:419–21. DOIPubMedGoogle Scholar
  11. Martinez-Martinez  L, Pascual  A, Jacoby  GA. Quinolone resistance from a transferable plasmid. Lancet. 1998;351:797–9. DOIPubMedGoogle Scholar
  12. Phillips  I, King  A, Shannon  K. Comparative in-vitro properties of the quinolones. In: Andriole VT, editor. The quinolones. 3rd ed. San Diego: Academic Press; 2000. p. 99–137.
  13. Blondeau  JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new ‘respiratory quinolones.’. J Antimicrob Chemother. 1999;43(Suppl B):S1–11. DOIGoogle Scholar
  14. Bauernfeind  A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1997;40:639–51. DOIPubMedGoogle Scholar
  15. Fung-Tomc  JC, Minassian  B, Kolek  B, Huczko  E, Aleksunes  L, Stickle  T, Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother. 2000;44:3351–6. DOIPubMedGoogle Scholar
  16. Zhanel  GG, Ennis  K, Vercaigne  L, Walkty  A, Gin  AS, Embil  J, A critical review of the fluoroquinolones. Drugs. 2002;62:13–59. DOIPubMedGoogle Scholar
  17. Hoban  DJ, Doern  GV, Fluit  AC, Roussel-Delvallez  M, Jones  RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis. 2001;32(Suppl. 2):S81–93. DOIPubMedGoogle Scholar
  18. Hoellman  DB, Kelly  LM, Jacobs  MR, Appelbaum  PC. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother. 2001;45:589–92. DOIPubMedGoogle Scholar
  19. Takahata  M, Shimakura  M, Hori  R, Kizawa  K, Todo  Y, Minami  S, In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2001;45:312–5. DOIPubMedGoogle Scholar
  20. Richardson  DC, Bast  D, McGeer  A, Low  DE. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:1911–4. DOIPubMedGoogle Scholar
  21. Huang  MB, Baker  CN, Banerjee  S, Tenover  FC. Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni and gram-negative bacteria resistant to antimicrobial agents. J Clin Microbiol. 1992;30:3243–8.PubMedGoogle Scholar
  22. Bast  DJ, Low  DE, Duncan  CL, Kilburn  L, Mandell  LA, Davidson  RJ, Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother. 2000;44:3049–54. DOIPubMedGoogle Scholar
  23. Weigel  LM, Anderson  GJ, Facklam  RR, Tenover  FC. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumonia. Antimicrob Agents Chemother. 2001;45:3517–23. DOIPubMedGoogle Scholar
  24. Fuchs  PC, Barry  AL, Brown  SD. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. Antimicrob Agents Chemother. 1996;40:1633–9.PubMedGoogle Scholar
  25. Davidson  R, Cavalcanti  R, Brunton  JL, Bast  DJ, de Azavedo  JCS, Kibsey  P, Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747–50. DOIPubMedGoogle Scholar
  26. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.PubMedGoogle Scholar
  27. Bartlett  JG, Dowell  SF, Mandell  LA, File  TM Jr, Musher  DM, Fine  MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347–82. DOIPubMedGoogle Scholar
  28. Warren  JW, Abrutyn  E, Hebel  JR, Johnson  JR, Schaeffer  AJ, Stamm  WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29:745–58. DOIPubMedGoogle Scholar
  29. Sahm  DF, Karlowsky  JA, Kelly  LJ, Critchley  IA, Jones  ME, Thornsberry  C, Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2 year longitudinal analysis. Antimicrob Agents Chemother. 2001;45:1037–42. DOIPubMedGoogle Scholar
  30. Jones  RN, Pfaller  MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 2000;31(Suppl 2):S16–23. DOIPubMedGoogle Scholar
  31. Thornsberry  C, Sahm  DF, Kelly  LJ, Critchley  IA, Jones  ME, Evangelista  AT, Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis. 2002;34(Suppl 1):S4–16. DOIPubMedGoogle Scholar
  32. Peterson  LR. Quinolone molecular structure-activity relationships: what have we learned about improving antibacterial activity. Clin Infect Dis. 2001;33(Suppl 3):S180–6. DOIPubMedGoogle Scholar
  33. Pestova  E, Beyer  R, Cianciotto  NP, Noskin  GA, Peterson  LR. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae for resistance to novel fluoroquinolones. Antimicrob Agents Chemother. 1999;43:2000–4.PubMedGoogle Scholar
  34. Lu  T, Zhao  X, Drlica  K. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8 methoxy group. Antimicrob Agents Chemother. 1999;43:2969–74.PubMedGoogle Scholar
  35. Pestova  E, Millichap  JJ, Noskin  GA, Peterson  LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother. 2000;45:583–90. DOIPubMedGoogle Scholar
  36. M’Zali  FH, Hawkey  PM, Thomson  CJ. The comparative in vitro activity of ciprofloxacin and levofloxacin against clinical strains of Pseudomonas aeruginosa. Clin Microbiol Infect 2000;6(Suppl 1):91. Abstract WeP122.
  37. Gilbert  DN, Kohlhepp  SJ, Slama  KA, Grunkemeier  G, Lewis  G, Dworkin  RJ, Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin and trovafloxacin. Antimicrob Agents Chemother. 2001;45:883–92. DOIPubMedGoogle Scholar
  38. Dalhoff  A, Schubert  S, Ullman  U. Dissociated resistance among fluoroquinolones. J Antimicrob Chemother 2001;47(Suppl 1):33. abstract P67.
  39. Nightingale  CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-dynamic characteristics. Pharmacotherapy. 2000;20:245–6. DOIPubMedGoogle Scholar
  40. Craig  WA. Does the dose matter? Clin Infect Dis. 2001;33(Suppl 3):S233–7. DOIPubMedGoogle Scholar
  41. Ciprofloxacin (Cipro) package insert. West Haven (CT): Bayer Corporation; 2001.
  42. Levofloxacin (Levaquin) package insert. Rarotam (NJ): Ortho-McNeil Pharmaceuticals; 2001.
  43. Moxifloxacin (Avelox) package insert. West Haven (CT): Bayer Corporation; 2001.
  44. Gatifloxacin (Tequin) package insert. Princeton (NJ): Bristol-Myers-Squibb Pharmaceuticals, Princeton; 2001.
  45. Thomas  JK, Forrest  A, Bhavnani  SM, Hyatt  JM, Cheng  A, Ballow  CH, Pharmacodynamic evaluation of factors associated the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998;42:521–7.PubMedGoogle Scholar
  46. Zhao  X, Drlica  K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33(Suppl 3):S147–56. DOIPubMedGoogle Scholar
  47. Blondeau  JM, Zhao  X, Hansen  G, Drlica  K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:433–8. DOIPubMedGoogle Scholar
  48. Hansen  G, Blondeau  JM, Drlica  K, Zhao  X. Evaluation of ciprofloxacin (C) and levofloxacin (L) by mutation prevention concentration (MPC) against 119 isolates of Pseudomonas aeruginosa (PA). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Dec 16–19, 2001. Washington: American Society for Microbiology; 2001. Abstract E-729.
  49. Peterson  LR, Postelnick  M, Pozdol  TL, Reisberg  B, Noskin  GA. Management of fluoroquinolone resistance in Pseudomonas aeruginosa—outcome of monitored use in a referral hospital. Int J Antimicrob Agents. 1998;10:207–14. DOIPubMedGoogle Scholar
  50. Rifenburg  RP, Paladino  JA, Bhavnani  SM, Den Haese  D, Schentag  JJ. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm. 1999;56:2217–23.PubMedGoogle Scholar
  51. Bhavnani  SM, Callen  WA, Forrest  A, Gilliland  KK, Collins  DA, Paladino  JA, An evaluation of fluoroquinolone expenditures and ciprofloxacin susceptibility of P. aeruginosa among U.S. hospitals. [Abstract 100]. Pharmacotherapy. 2001;21(Suppl):371a.
  52. Peterson  L. Stability of antimicrobial activity against emerging resistance in Gram-negative pathogens recovered from hospitalized patients. In: Program and Abstracts from the 10th International Congress on Infectious Diseases, Hong Kong. March 11–14, 2002. Boston: International Congress of Infectious Diseases; 2002. Abstract 11.029.
  53. Austin  DJ, Kristinsson  KG, Anderson  RM. The relationship between the volume of drug consumption in human communities and the frequency of antibiotic resistance. Proc Natl Acad Sci U S A. 1999;96:1152–6. DOIPubMedGoogle Scholar
  54. Zambrano  CH, Postelnik  MJ, Noskin  GA. Relationship between antimicrobial usage and susceptibility in specific patient care areas: a 3-year assessment. Infectious Diseases Society of America 39th Annual Meeting, San Francisco, CA, Oct 25–28, 2001. Alexandria (VA): Infectious Diseases Society of American; 2001. Abstract 496.
  55. Iannini  PB, Tillotson  GS. Impact of quinolone substitution on Pseudomonas aeruginosa resistance, antimicrobial usage and hospital costs: presented at the Antimicrobial Chemotherapy and Clinical Practice meeting, Genova, Italy, Oct 21–24, 2001. [Abstract 111]. Pharmacotherapy. 2001;21(Suppl):371.
  56. Fridkin  SK, Steward  CD, Edwards  JR, Pryor  ER, McGowan  JE, Archibald  LK, Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis. 1999;29:245–52. DOIPubMedGoogle Scholar
  57. Hill  HA, Haber  MJ, McGowan  JE, Fridkin  SK, Edwards  JR, Tenover  FC, A link between quinolone use and resistance in P. aeruginosa?: preliminary data from Project ICARE. Infectious Diseases Society of America 39th Annual Meeting, San Francisco, CA, Oct 25-28, 2001. Alexandria (VA): Infectious Diseases Society of America; 2001. Abstract 495.
  58. Ho  PL, Que  TL, Tsang  DN, Ng  T-K, Chow  K-H, Seto  W-H. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother. 1999;43:1310–3.PubMedGoogle Scholar
  59. Ho  PL, Yung  RWH, Tsang  DN, Que  TL, Ho  M, Seto  WH, Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother. 2001;48:659–65. DOIPubMedGoogle Scholar
  60. Chen  DK, McGeer  A, de Azavedo  JC, Low  DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233–9. DOIPubMedGoogle Scholar
  61. Ball  AP, Tillotson  GS. Lower respiratory tract infection therapy – the role of ciprofloxacin. J Int Med Res. 1995;23:315–27.PubMedGoogle Scholar
  62. Wortmann  GW, Bennett  SP. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae. Clin Infect Dis. 1999;29:1599–600. DOIPubMedGoogle Scholar
  63. Fishman  NO, Suh  B, Weigel  LM, Lorber  B, Gelone  S, Truant  AL, Three levofloxacin treatment failures of pneumococcal respiratory tract infections. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept 26–29, 1999. Washington: American Society for Microbiology; 1999. Abstract 825.
  64. Kuehnert  MJ, Nolte  FS, Perlino  CA. Fluoroquinolone resistance in Streptococcus pneumoniae. Ann Intern Med. 1999;131:312–3.PubMedGoogle Scholar
  65. Urban  C, Rahman  N, Zhao  X, Mariano  N, Segal-Maurer  S, Drlica  K, Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis. 2001;184:794–8. DOIPubMedGoogle Scholar
  66. Empey  PE, Jennings  HR, Thornton  AC, Rapp  RP, Evans  ME. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother. 2001;35:687–90. DOIPubMedGoogle Scholar
  67. Piper  J, Couch  K, Tuttle  D, Steele-Moore  L. Epidemiology and clinical outcomes of patients with levofloxacin resistant pneumococcus. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Dec 16–19, 2001. Washington: American Society for Microbiology; 2001. Abstract L-902.
  68. Kays  MB, Smith  DW, Wack  MF, Denys  GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy. 2002;22:395–9. DOIPubMedGoogle Scholar
  69. Ross  JJ, Worthington  MG, Gorbach  SL. Resistance to levofloxacin and failure of treatment of pneumoccal pneumoia. N Engl J Med. 347:65–6.
  70. Davies  BI, Maesen  FPV. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J Antimicrob Chemother. 1999;43(Suppl C):83–90. DOIPubMedGoogle Scholar
  71. Sullivan  JG, McElroy  AD, Honsinger  RW, McAdoo  M, Harrison  BJ, Plouffe  JF, Treating community-acquired pneumonia with once daily gatifloxacin vs once-daily levofloxacin. J Respir Dis. 1999;20(Suppl):S49–59.
  72. Weiss  K, Restieri  C, Gauthier  R, Laverdiere  M, McGeer  A, Davidson  R, A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis. 2001;33:517–22. DOIPubMedGoogle Scholar
  73. Ho  PL, Tse  WS, Tsang  KWT, Kwok  TK, Ng  TK, Cheng  VCC, Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 2001;32:701–7. DOIPubMedGoogle Scholar
  74. Thomson  KS. Minimizing quinolone resistance: are the new agents more or less likely to cause resistance? J Antimicrob Chemother. 2000;45:719–23. DOIPubMedGoogle Scholar

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external